Sign in
Taking peopleNo phase

Medium-term Effects of Treatments in Autoimmune Encephalitis

Key facts

Who runs it
Hospices Civils de Lyon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
200 people, planned
Started
1 Sept 2024
Expected to end
1 Mar 2027
Type of study
Observational, 6 groups
Treatments tested
  • We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
Record updated
20 August 2025

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP
  • Untreated or with a decision to treat within the previous 30 days

Who cannot take part

  • Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his/her clinical data

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.

The 6 groups in the trial

  • group 1 : Patients with NMDAR encephalitis

    Patients with untreated anti-NMDAR encephalitis or with a decision to treat within the previous 30 days

    Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).

  • group 2 : Patients with GAD encephalitis

    Patients with untreated anti-GAD encephalitis or with a decision to treat within the previous 30 days

    Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).

  • group 3 : Patients with LGI1 encephalitis

    Patients with untreated anti-LGI1 encephalitis or with a decision to treat within the previous 30 days

    Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).

  • group 4 : Patients with IgLON5 encephalitis

    Patients with untreated anti-IgLON5 encephalitis or with a decision to treat within the previous 30 days

    Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).

  • group 5 : Patients with GFAP encephalitis

    Patients with untreated anti-GFAP encephalitis or with a decision to treat within the previous 30 days

    Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).

  • group 6 : Patients with CASPR2 encephalitis

    Patients with untreated anti-CASPR2 encephalitis or with a decision to treat within the previous 30 days

    Treatment: We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study
Record updated
20 August 2025